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-It has been shown a relationship between a deregulation in cholesterol homeostasis and 
neurodegenerative diseases 
-Although having some common points, there is no reason to say that these neurodegenerative diseases are 
related 
                                                Cholesterol regulation is affected in different pathways on each disease 
-These disorders do not affect the same brain zones 
- In all four diseases should be increased the synthesis of 24S-OH-C to prevent brain cholesterol 
accumulation, probably with a common treatment 
-Due to cholesterol homeostasis complexity it is difficult to find a proper treatment. 
No common 
therapy 
Conclusions 
Cholesterol homeostasis role in 
neurodegenerative diseases 
Brain’s cholesterol homeostasis deregulations are common in several neurodegenerative diseases. This study aims to find any relationship between 
brain’s cholesterol regulation and neurodegenrative disorders comparing some of them: Alzheimer’s Disease, Huntington’s Disease, Niemann-Pick type 
C Disease and Smith-Lemli Opitz syndrome. This comparison would allow us to guide a pharmacology research destined to solve this problem. 
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Cholesterol in Central Nervous System 
Cholesterol Biosynthesis Pathway Cholesterol Regulation 
 
§Due to plasma lipoproteins can not go through the Blood Brain Barrier (BBB) almost 
all brain cholesterol is synthesized in situ 
 
§ LXR is a transcription factor that regulates several cholesterol homeostasis 
implicated genes 
 
§ Cholesterol efflux from glial cells is mediated by ABC transporters 
 
§ Cholesterol exchange between brain cells is mediated by lipoproteins derived from 
glia. Outside cells, cholesterol and phospholipids associates with apolipoprotein E 
(ApoE) 
 
 
 
§ Cholesterol excess is removed from brain 
 
CYP46 catalyzes 24S-hidroxycholesterol (24S-OH-C) formation           It can go through  
the BBB 
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Enzymes with an orange asterisk are regulated by SREBP. Red squares indicates 
enzymes or products affected by Alzheimer’s Disease. Green squares indicates 
enzymes affected by Smith-Lemli Opitz Syndrome. Red, green, orange and black 
arrows indicate collateral effects of that alterations.  
ApoE-containing lipoproteins are recognized by LDL family 
receptors in neurons 
§  HTT mutated protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SREBP interacts with SCAP. SREBP activates cholesterogenic genes 
transcription. In presence of sterols in cell, sterols bind SCAP, 
preventing SCAP-SREBP complex. SCAP and INSIG 1 interact when 
cholesterol is present, inhibiting its biosynthesis. GP78 is required 
for ubiquitination and degradation of INSIG 1 in cholesterol deficient 
cells. Valenza, M. et. al. 2011. 
 
§       [24S-OH-C] 
Alzheimer’s Disease Huntington’s Disease Niemann-Pick type C Disease 
§ Extracellular deposits of amyloid β fibrils           accumulation of 
amyloid β-peptide (Aβ) 
•ApoE seems to be implicated by two possible models 
              Puglielli, L. et. al. 2003. 
§Changes in neuronal cytoskeleton 
 
§ Cholesterol synthesis 
 
§ [24S-OH-C] 
Aβ interact with ApoE-
containing lipoproteins before 
being endocytosed by neurons. 
Inside cells, free ApoE 
associates with Aβ and 
promotes its aggregation. 
ApoE modify cholesterol 
levels in cells.
High cholesterol levels 
within cell up-regulates Aβ 
formation. 
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§  Mutation in npc1/2 genes 
 
 
 
 
 
 
 
     
 
 
NPC1 and NPC2 are required for cholesterol release from 
lysosomes/late endosomes. Vance JE. 2012 (modified) 
 
§     [24S-OH-C] 
 
 
 
 
§ 7-dehydrocholesterol reductase (DHCR7) mutation 
 
 
 
 
 
 
§       [24S-OH-C] 
Smith-Lemli Opitz Syndrome 
NPC1 or NPC2 proteins deficiency in cells 
Cholesterol accumulation in 
lysosomes/late endosomes 
Intracellular cholesterol 
transport alteration 
Cholesterol 
Synthesis 
7-dehydrocholesterol 
Hmgcr inhibition  
hyperphosphorylation 
of Tau protein 
low lanosterol levels and 
seladin-1 expression 
